SCHEMBL95043

SCHEMBL95043

[CH2]c1ccc(C(=O)NCc2ccc(Cl)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
CYP2C19 P33261 2/20 0.68
CYP1A2 P05177 1/20 0.68
RAB9A P51151 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.68
EPHX2 P34913 2/20 0.58
PPARG P37231 1/20 0.58
CYP3A4 P08684 1/20 0.57
MAPK14 Q16539 1/20 0.57
TSHR P16473 1/20 0.56
NAMPT P43490 1/20 0.56
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8987867 0.91 MEN1 (0.78) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL28658583 0.90 MEN1 (0.68) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL2832296 0.85 MAPT (0.72) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL9119912 0.85 RAB9A (0.71) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL96062 0.84 NPC1 (0.75) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL19630500 0.83 MEN1 (0.72) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL5647805 0.83 MEN1 (0.68) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL13947380 0.83 MEN1 (0.72) MEN1KMT2ACYP2C19CYP1A2RAB9A
SCHEMBL95283 0.83 L3MBTL1 (0.67) MEN1KMT2ACYP2C19CYP1A2SMN1; SMN2
SCHEMBL25872270 0.83 MEN1 (0.72) MEN1KMT2ACYP2C19CYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB MEN1 4401/4885KMT2A 1059/4885CYP2C19 3445/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 MEN1 3912/4885KMT2A 2732/4885CYP2C19 1094/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 MEN1 3912/4885KMT2A 2732/4885CYP2C19 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.